CSPC Pharmaceutical Group Ltd (1093.HK)
Company Info
Highlights
HK$70.91B
HK$0.24
15.92
8.23
HK$4.27 - HK$7.62
HK$6.76
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in CSPC Pharmaceutical Group Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
CSPC Pharmaceutical Group Ltd (1093.HK) returned 20.38% year-to-date (YTD) and -9.79% over the past 12 months. Over the past 10 years, 1093.HK returned -1.25% annually, underperforming the S&P 500 benchmark at 10.31%.
1093.HK
20.38%
20.89%
7.50%
-9.79%
-16.41%
-1.25%
^GSPC (Benchmark)
-4.26%
11.24%
-5.02%
8.55%
14.02%
10.31%
Monthly Returns
The table below presents the monthly returns of 1093.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -6.09% | 5.37% | 4.88% | 24.09% | -6.53% | 20.38% | |||||||
| 2024 | -20.94% | 6.62% | 0.49% | 5.37% | 4.46% | -6.18% | -6.43% | -17.18% | 25.52% | -2.40% | -11.83% | -6.11% | -31.26% |
| 2023 | 9.02% | -5.71% | -8.42% | 3.37% | -14.54% | 1.49% | -4.70% | -9.09% | -0.32% | 18.99% | 3.22% | 2.98% | -7.80% |
| 2022 | 11.57% | -2.12% | -2.16% | -10.50% | 5.02% | -7.26% | 10.27% | -6.99% | -1.38% | 3.73% | 23.79% | -17.92% | -0.70% |
| 2021 | -0.13% | 2.27% | 16.05% | 2.34% | 27.64% | -7.72% | -6.76% | -5.82% | -4.58% | -12.85% | -0.74% | 4.83% | 8.57% |
| 2020 | -6.89% | 2.66% | -12.61% | -0.77% | -1.43% | -2.80% | 11.07% | 5.90% | -12.68% | -45.53% | -7.34% | 4.76% | -56.88% |
| 2019 | 19.12% | -0.45% | 8.96% | 3.56% | -15.81% | -0.32% | 9.21% | 13.95% | 0.38% | 28.02% | -11.56% | 4.27% | 65.60% |
| 2018 | 10.01% | 4.15% | 15.32% | -3.12% | 21.92% | -3.46% | -13.50% | -3.41% | -16.06% | -0.48% | -4.23% | -28.66% | -28.16% |
| 2017 | 5.80% | 8.45% | 7.16% | 6.09% | 8.54% | -2.23% | 6.84% | 0.33% | 7.04% | 3.67% | 14.31% | 1.81% | 91.61% |
| 2016 | -17.42% | -5.35% | 13.41% | -1.57% | 2.46% | -1.74% | -2.75% | 12.22% | 3.05% | 3.61% | 3.61% | -0.60% | 5.40% |
| 2015 | -4.24% | -3.21% | 3.47% | 22.87% | -0.35% | -4.01% | -7.31% | 0.00% | -4.37% | 6.63% | 0.69% | 8.64% | 16.54% |
| 2014 | 5.07% | 8.86% | -1.86% | -6.11% | -4.67% | 1.31% | -2.58% | 7.46% | -0.77% | 11.04% | -3.36% | -0.87% | 12.48% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 1093.HK is 49, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for CSPC Pharmaceutical Group Ltd (1093.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
CSPC Pharmaceutical Group Ltd provided a 5.24% dividend yield over the last twelve months, with an annual payout of HK$0.30 per share. The company has been increasing its dividends for 10 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | HK$0.30 | HK$0.30 | HK$0.25 | HK$0.20 | HK$0.17 | HK$0.16 | HK$0.09 | HK$0.08 | HK$0.06 | HK$0.06 | HK$0.05 | HK$0.04 |
Dividend yield | 5.24% | 6.30% | 3.44% | 2.44% | 2.01% | 2.05% | 0.50% | 0.69% | 0.40% | 0.69% | 0.66% | 0.61% |
Monthly Dividends
The table displays the monthly dividend distributions for CSPC Pharmaceutical Group Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | |||||||
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.14 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.16 | HK$0.00 | HK$0.00 | HK$0.30 |
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.11 | HK$0.00 | HK$0.00 | HK$0.14 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.25 |
| 2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.10 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.10 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.20 |
| 2021 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.09 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.08 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.17 |
| 2020 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.13 | HK$0.00 | HK$0.00 | HK$0.04 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.16 |
| 2019 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.09 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.09 |
| 2018 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.08 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.08 |
| 2017 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.06 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.06 |
| 2016 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.06 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.06 |
| 2015 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.05 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.05 |
| 2014 | HK$0.04 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.04 |
Dividend Yield & Payout
Dividend Yield
CSPC Pharmaceutical Group Ltd has a dividend yield of 5.24%, which is quite average when compared to the overall market.
Payout Ratio
CSPC Pharmaceutical Group Ltd has a payout ratio of 124.02%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the CSPC Pharmaceutical Group Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CSPC Pharmaceutical Group Ltd was 80.66%, occurring on Jan 15, 2025. The portfolio has not yet recovered.
The current CSPC Pharmaceutical Group Ltd drawdown is 74.47%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -80.66% | Jun 6, 2018 | 1628 | Jan 15, 2025 | — | — | — |
| -78.03% | Apr 28, 2010 | 522 | Jun 5, 2012 | 386 | Dec 30, 2013 | 908 |
| -74.31% | Jun 20, 2003 | 738 | Jun 13, 2006 | 235 | May 25, 2007 | 973 |
| -72.98% | Oct 4, 2007 | 260 | Oct 27, 2008 | 213 | Sep 4, 2009 | 473 |
| -72.06% | Sep 14, 1999 | 495 | Sep 18, 2001 | 331 | Jan 22, 2003 | 826 |
Volatility
Volatility Chart
The current CSPC Pharmaceutical Group Ltd volatility is 22.75%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CSPC Pharmaceutical Group Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of CSPC Pharmaceutical Group Ltd, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -14.1%.
Valuation
The Valuation section provides an overview of how CSPC Pharmaceutical Group Ltd is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 1093.HK, comparing it with other companies in the Drug Manufacturers - General industry. Currently, 1093.HK has a P/E ratio of 15.9. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 1093.HK compared to other companies in the Drug Manufacturers - General industry. 1093.HK currently has a PEG ratio of 8.2. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 1093.HK relative to other companies in the Drug Manufacturers - General industry. Currently, 1093.HK has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 1093.HK in comparison with other companies in the Drug Manufacturers - General industry. Currently, 1093.HK has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |